SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma-Reference-Cited by-同舟云学术

SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma

Published:2015-12-28 Issue:6 Volume:122 Page:868-874
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Schuetze Scott M.¹,Wathen J. Kyle²,Lucas David R.³,Choy Edwin⁴,Samuels Brian L.⁵,Staddon Arthur P.⁶,Ganjoo Kristen N.⁷,von Mehren Margaret⁸,Chow Warren A.⁹,Loeb David M.¹⁰,Tawbi Hussein A.¹¹,Rushing Daniel A.¹²,Patel Shreyaskumar R.¹³,Thomas Dafydd G.¹⁴,Chugh Rashmi¹,Reinke Denise K.¹⁵,Baker Laurence H.¹

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine; University of Michigan; Ann Arbor Michigan

2. Department of Biostatistics; Johnson & Johnson; New Brunswick New Jersey

3. Anatomic Pathology; University of Michigan; Ann Arbor Michigan

4. Division of Hematology/Oncology, Department of Medicine; Massachusetts General Hospital; Boston Massachusetts

5. Northwest Oncology; Post Falls Idaho

6. Division of Hematology/Oncology, Department of Medicine; University of Pennsylvania School of Medicine; Philadelphia Pennsylvania

7. Medical Oncology, Stanford Medical Institute; Stanford California

8. Division of Medical Oncology and Hematology, Fox Chase Cancer Center; Philadelphia Pennsylvania

9. Department of Medical Oncology and Therapeutics Research; City of Hope Medical Center; Duarte California

10. Division of Pediatric Oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University; Baltimore Maryland

11. Division of Hematology/Oncology, Department of Medicine; University of Pittsburgh School of Medicine; Pittsburgh Pennsylvania

12. Divison of Hematology/Oncology, Department of Medicine; Indiana University; Indianapolis Indiana

13. Department of Sarcoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

14. Molecular Pathology; University of Michigan; Ann Arbor Michigan

15. Sarcoma Alliance for Research through Collaboration; Ann Arbor Michigan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29858/fullpdf

Reference24 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

3. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002 [corrected];Maki;J Clin Oncol,2007

4. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;Graaf;Lancet,2012

5. Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors;Weiner;Ann Surg Oncol,1994

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials;Journal of Clinical Oncology;2024-09-01

2. Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents;Targeted Oncology;2024-07-02

3. Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma;Cells;2024-06-04

4. Contemporary Approach to Neurofibromatosis Type 1–Associated Malignant Peripheral Nerve Sheath Tumors;American Society of Clinical Oncology Educational Book;2024-06

5. Orbital malignant peripheral nerve sheath tumor: A case report and review;Oman Journal of Ophthalmology;2024-05